Reduction in the Number of Procedures and Hospitalizations and Increase in Cancer Mortality During the COVID-19 Pandemic in Brazil

Fonseca, Gabriela A.; Normando, Paulo G.; Loureiro, Luiz Victor Maia; Rodrigues, Rodrigo Elton Ferreira; Oliveira, Victor Agripino; Melo, Marcelo Dantas Tavares de; Santana, Isabelle

doi:10.1200/go.20.00471

Cited by 23 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evaluating hospitalization for TB in our hospital over the period March-August 2020 with the previous year, a significative reduction in hospitalizations-up to 40%-emerged. This evidence is consistent with data form other Italian [15][16][17] and regional hospital that have confirmed on a large regional scale the reduction in TB cases in 2020 vs. 2019 (Department of Epidemiology of Lazio Regional Health Service, unpublished data). Also, from the experience of other epidemics, there are possible explanations [10][11][12][13][14][15][16][17][18][19].…”

Section: Discussionsupporting

confidence: 92%

“…This evidence is consistent with data form other Italian [15][16][17] and regional hospital that have confirmed on a large regional scale the reduction in TB cases in 2020 vs. 2019 (Department of Epidemiology of Lazio Regional Health Service, unpublished data). Also, from the experience of other epidemics, there are possible explanations [10][11][12][13][14][15][16][17][18][19]. The reorganization of hospital/health services under pressure from COVID-19 resulting in the conversion of tuberculosis wards in COVID-19 unit-had a major indirect impact on the path of care of TB patients, explaining the observed reduction in hospitalization.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital

et al. 2021

View full text Add to dashboard Cite

Background: The WHO advised that the impact of COVID-19 pandemic on TB services was estimated to be dramatic due to the disruption of TB services. Methods: A retrospective data collection and evaluation was conducted to include all the patients hospitalized for TB at INMI from 9 March to 31 August 2020 (lockdown period and three months thereafter). For the purpose of the study, data from patients hospitalized in the same period of 2019 were also collected. Results: In the period of March–August 2019, 201 patients were hospitalized with a diagnosis of TB, while in the same period of 2020, only 115 patients, with a case reduction of 43%. Patients with weight loss, acute respiratory failure, concurrent extrapulmonary TB, and higher Timika radiographic scores were significantly more frequently hospitalized during 2020 vs. 2019. The median patient delay was 75 days (IQR: 40–100) in 2020 compared to 30 days (IQR: 10–60) in 2019 (p < 0.01). Diagnostic delays in 2020 remain significant in the multiple logistic model (AOR = 6.93, 95%CI: 3.9–12.3). Conclusions: Our experience suggests that COVID-19 pandemic had an impact on TB patient care in terms of higher diagnostic delay, reduction in hospitalization, and a greater severity of clinical presentations.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A higher than expected mortality rate (33%) of patients with cancer in treatment has also been documented in Brazil. 9 …”

Section: Perspective From Brazilmentioning

confidence: 99%

“…A higher than expected mortality rate (33%) of patients with cancer in treatment has also been documented in Brazil. 9 Measures to reduce hospital visits and risk of infection for the management of patients with cancer during the pandemic include the following: (1) postponing treatments and surgeries in patients for whom a delay would not compromise outcomes, (2) substituting intravenous treatments for oral therapies whenever possible, (3) prioritizing radiotherapy hypofractionation, (4) ensuring measures to reduce contagion such as social distancing and use of CONTEXT Key Objective ASCO's International Quality Steering Group convened a series of webinars to review the impact of the COVID-19 pandemic and its stresses that have disproportionately affected cancer care outside of the United States.…”

Section: Perspective From Brazilmentioning

confidence: 99%

“…AFFILIATIONS 1 Stanford Cancer Institute, Stanford University, Stanford, CA 2 Hospital Sirio Libanes, São Paulo, Brazil 3 Hematology Oncology at The Kirklin Clinic of University of Alabama, Birmingham, AL 4 Mediclinic City Hospital Dubai, Dubai, United Arab Emirates 5 Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 6 Manila Central University-FDTMF Hospital, Caloocan, Philippines 7 Medical Oncology Hematology Consultants, Wilmington, DE 8 Bon Secours Cork Cancer Centre, Cork, Ireland 9 Teladoc Health, Washington, DC 10 University of the Witwatersrand, Johannesburg, South Africa 11 Clinica AMO Salvador, Brazil 12 Hospital Escuela, University of Honduras, Tegucigalpa, Honduras…”

Section: Authors' Disclosures Of Potential Conflicts Of Interestmentioning

confidence: 99%

See 1 more Smart Citation

Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care

Blayney

Bariani

Das

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

This report from ASCO's International Quality Steering Group summarizes early learnings on how the COVID-19 pandemic and its stresses have disproportionately affected cancer care delivery and its delivery systems across the world. This article shares perspectives from eight different countries, including Austria, Brazil, Ghana, Honduras, Ireland, the Philippines, South Africa, and the United Arab Emirates, which provide insight to their unique issues, challenges, and barriers to quality improvement in cancer care during the pandemic. These perspectives shed light on some key recommendations applicable on a global scale and focus on access to care, importance of expanding and developing new treatments for both COVID-19 and cancer, access to telemedicine, collecting and using COVID-19 and cancer registry data, establishing measures and guidelines to further enhance quality of care, and expanding communication among governments, health care systems, and health care providers. The impact of the COVID-19 pandemic on cancer care and quality improvement has been and will continue to be felt across the globe, but this report aims to share these experiences and learnings and to assist ASCO's international members and our global fight against the pandemic and cancer.

show abstract

Impact of the COVID‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

et al. 2022

View full text Add to dashboard Cite

Purpose To determine if the COVID‐19 pandemic has further exacerbated racial disparities in late‐stage presentation of breast, colorectal, lung, and prostate cancers. Methods We conducted a registry‐based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019–June 2019 (pre‐COVID‐19) and March 2020–June 2020 (early‐COVID‐19). We compared the volume of new diagnoses and stage at presentation according to race between both periods. Results During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre‐COVID‐19 period included 2120 (64.2%), and the early‐COVID‐19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre‐COVID‐19, 16.8% were diagnosed with metastatic disease, versus 20.4% early‐COVID‐19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non‐significant proportional decline of 1.9% in Black patients diagnosed with non‐metastatic breast, colorectal, lung, and prostate cancers early‐COVID‐19 ( p = 0.71) and a non‐significant proportional increase of 7% in Black patients diagnosed with metastatic disease ( p = 0.71). Difference‐in‐difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients. Conclusion While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID‐19 pandemic, the impact was similar for White and Black patients.

show abstract

Reduction in the Number of Procedures and Hospitalizations and Increase in Cancer Mortality During the COVID-19 Pandemic in Brazil

Cited by 23 publications

References 12 publications

Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital

Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital

Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care

Impact of the COVID‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

Contact Info

Product

Resources

About